Significant Ownership of ASTRAZENECA PLC
- Large-stake filing summary
-
- Recent SEC Schedule 13D/G filings for ASTRAZENECA PLC focus on large-stake beneficial ownership disclosures and amendments.
- Use this view to spot new large holders, amended positions, and activist-style ownership evidence.
- Manager signature
- /s/ Matthew Bowden - Matthew Bowden / Company Secretary
- Manager location
- Cambridge
Large-stake snapshot
1 signal
Manager
Names, identifiers, and filing context for this profile.
2 identity fields
Follow Filing Activity
Follow ASTRAZENECA PLC with Pro and return when a new Schedule 13D/G filing changes the record on this page.
Pro alert delivery is coming soon and remains tied to source-backed filing changes rather than inferred market advice.
CIK context first
Continue from ASTRAZENECA PLC
Significant Ownership of ASTRAZENECA PLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| CLLS | Cellectis S.A. | Ordinary shares, nominal value of EUR0.05 per ordinary share | 44% | $66,440,000 | 44,000,000 | AstraZeneca PLC | 23 Jan 2025 | ||
| Innate Pharma SA | Ordinary Shares, EUR0.05 nominal value per share | 8.3% | 7,825,501 | AstraZeneca PLC | 22 Dec 2025 | ||||
| MNPR | Monopar Therapeutics Inc. | Common Stock, $0.001 par value per share | 7.8% | $34,126,392 | 522,667 | AstraZeneca PLC | 31 Dec 2025 | ||
| CDT | Conduit Pharmaceuticals Inc. | Common Stock, par value $0.0001 per share | 1.1% | $3,340 | 73,892 | AstraZeneca PLC | 31 Mar 2025 |
Schedules 13D/G Reported by ASTRAZENECA PLC:
| Sym | Target | Class | Ownership | Change | Current shares | Change | Value | Reporting name | Form | Report period | Filing date |
|---|
Schedule rows are parsed from SEC 13D/G filings. Open the linked filing or target page to verify the reported ownership and shares.